Eclipsebio
PrivateLast Round
Grant
Jan 13, 2025
Total Funding Raised
$19.03M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Eclipsebio operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Grant round in January 2025.
Eclipsebio is a biotechnology company that develops first-in-class technologies, analyses, and platforms for the development of RNA-based and RNA-targeting therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eclipsebio Comparables
Compare Eclipsebio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alida Biosciences | 84% | |
| Atomic AI | 83% | |
| Envisagenics | 81% |
For institutional investors. Book with your work email.
Eclipsebio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 13, 2025 | ||||
| Grant | Jul 1, 2024 | ||||
| Series A | Mar 15, 2022 | ||||
| Seed | Jun 5, 2020 | ||||
| Grant | Sep 17, 2019 | ||||
Grant | Sep 20, 2017 |
For institutional investors. Book with your work email.
Eclipsebio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Phoenix Venture Partners | Series A |
| NIH RADx | Grant |
| Alexandria Venture Investments | Series A |
| iGlobe Partners | Series A |
| National Institute of General Medical Sciences | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 42% MoM, reaching 10.3K.
- Apr 21, 2026
Launched eCOMPASS platform for AI-driven RNA therapeutic development.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesSep 10, 2026
Eclipse Bioinnovations launches eSTRAND RNA QC(TM), a nanopore-based assay that uses direct RNA sequencing to characterize RNA across multiple attributes, in Sep '26.
For institutional investors. Book with your work email.
Eclipsebio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Eclipsebio's valuation, stock price, and market status.
Is Eclipsebio a public or private company?
Eclipsebio is a private company.
What is the current stock price of Eclipsebio?
Eclipsebio is a private company, so its shares have no public market price. Caplight tracks Eclipsebio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eclipsebio worth (valuation)?
Valuation information for Eclipsebio is not publicly available.
Can I buy Eclipsebio stock?
Eclipsebio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eclipsebio's last funding round?
Eclipsebio's most recent funding round was Grant on January 13, 2025.
Who are the main investors in Eclipsebio?
Key investors in Eclipsebio include Alexandria Venture Investments, iGlobe Partners.
Will Eclipsebio IPO soon?
No public IPO plans have been announced for Eclipsebio.
How can I track Eclipsebio secondary market activity?
Caplight tracks bids, offers, and trades in Eclipsebio's shares on secondary markets.